Photo of Hagop Kantarjian from mdanderson.org
Mar 10, 2024, 20:49
Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia
Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, recently posted on X:
“In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. ”
Source: Hagop Kantarjian/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 6, 2024, 12:32
Oct 6, 2024, 12:29
Oct 6, 2024, 12:26
Oct 6, 2024, 12:24
Oct 6, 2024, 12:18
Oct 6, 2024, 12:15
Oct 6, 2024, 11:43
Oct 6, 2024, 11:33
Oct 6, 2024, 11:20
Oct 6, 2024, 11:11